Study of FT819 for B-cell autoimmune diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 70 years old.
- You have a diagnosis of active lupus, vasculitis, myositis, or scleroderma that is moderate to severe.
- You have tried at least two treatments that did not work well enough.
- Your organs (heart, lungs, liver, kidneys) are working well enough to handle the treatment.
- You weigh at least 110 pounds (50 kilograms).
- You are not pregnant or nursing, and have no recent serious infections, cancer, or prior CAR T-cell therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (FT839) designed to target and reset the immune system's B cells to help treat moderate to severe autoimmune diseases that haven't improved with standard treatments. It's an early-phase study, so the main goals are to see if it's safe and if it helps control the disease.
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial is testing whether a type of immune cell therapy called CAR-T cells can help people with severe autoimmune diseases that have not improved with standard treatments. It may offer a new option for conditions like lupus, Sjogren's syndrome, or vasculitis when other therapies have failed.
This trial is testing a new type of cell therapy called universal CAR-T cells combined with immunosuppressant drugs for people with hard-to-treat autoimmune diseases. The goal is to see if this approach is safe and can help reduce disease activity.
This trial tests a new treatment called CAR-T cell therapy for people with severe autoimmune rheumatic diseases that have not improved with other treatments. The therapy uses your own immune cells, which are modified in a lab to attack the cells causing the disease, potentially reducing symptoms and improving quality of life.
Hear when a new Idiopathic Inflammatory Myositis (IIM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.